Hexarelin vs. GHRP-6: Research Comparison of GH Secretagogues
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
Overview
Hexarelin and GHRP-6 are both first-generation growth hormone-releasing peptides (GHRPs) that act as ghrelin receptor agonists. While they share a common receptor target, their pharmacological profiles differ in important ways that influence their research applications.
Shared Mechanism: Ghrelin Receptor Agonism
Both hexarelin and GHRP-6 are synthetic hexapeptides that bind to the ghrelin receptor (GHS-R1a), triggering GH release from the anterior pituitary. This shared mechanism means both compounds stimulate pulsatile GH secretion, partially suppress somatostatin tone, and elevate plasma GH within 15-30 minutes of administration.
Potency Comparison
| Parameter | Hexarelin | GHRP-6 | |-----------|----------|--------| | GH-releasing potency | High (reference compound) | Moderate (~50% of hexarelin) | | GH pulse amplitude | Higher | Moderate | | Desensitization rate | Faster | Slower | | Half-life | ~30 min | ~15-20 min |
The higher potency of hexarelin comes with a trade-off: it desensitizes the ghrelin receptor more rapidly with repeated dosing.
Selectivity: Cortisol and Prolactin
| Hormone | Hexarelin | GHRP-6 | Ipamorelin | |---------|----------|--------|-----------| | GH elevation | +++ | ++ | ++ | | Cortisol elevation | +++ | ++ | + (minimal) | | Prolactin elevation | ++ | ++ | + (minimal) |
Both hexarelin and GHRP-6 produce significant cortisol and prolactin elevations, which is a key limitation compared to the more selective ipamorelin.
Hexarelin's Cardiovascular Research
One of the most distinctive aspects of hexarelin research is its cardiovascular effects, which appear to be independent of GH secretion:
Cardiac GHS-R1a binding: The heart expresses ghrelin receptors, and hexarelin demonstrates direct cardioprotective effects in preclinical models.
Reduced infarct size: Studies in rodent models of myocardial ischemia-reperfusion injury showed that hexarelin administration reduced infarct size and improved cardiac function.
CD36 receptor binding: Hexarelin has been shown to bind the scavenger receptor CD36, which may contribute to its cardioprotective and anti-atherogenic effects.
GHRP-6: Appetite and Gastric Motility Research
GHRP-6 has been extensively studied for its effects on appetite and gastrointestinal function. It is one of the most potent appetite stimulants among GHRPs, mediated through hypothalamic ghrelin receptor activation. Research has also shown that GHRP-6 stimulates gastric emptying and motility.
Research Applications Summary
| Application | Hexarelin | GHRP-6 | |-------------|----------|--------| | GH secretion studies | Excellent (high potency) | Good | | Cardiovascular research | Excellent (unique) | Limited | | Appetite/GI research | Limited | Excellent | | Chronic protocols | Limited (desensitization) | Better |
Summary
Hexarelin and GHRP-6 are complementary research tools. Hexarelin's higher potency and unique cardiovascular effects make it valuable for cardiac and GH secretion research, while GHRP-6's appetite-stimulating effects make it the preferred tool for GI and appetite research.
See Also: Growth Hormone Peptides: GHRPs, GHRHs and Secretagogues | Ipamorelin + CJC-1295 Combination Research
Was this article helpful?
Click a star to rate
All compounds referenced in this article are available as research-grade peptides, independently verified by Freedom Diagnostics.